DK1033981T3 - Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet - Google Patents

Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet

Info

Publication number
DK1033981T3
DK1033981T3 DK98953570T DK98953570T DK1033981T3 DK 1033981 T3 DK1033981 T3 DK 1033981T3 DK 98953570 T DK98953570 T DK 98953570T DK 98953570 T DK98953570 T DK 98953570T DK 1033981 T3 DK1033981 T3 DK 1033981T3
Authority
DK
Denmark
Prior art keywords
toxicity
reducing
antineoplastic agents
agents
formulations
Prior art date
Application number
DK98953570T
Other languages
Danish (da)
English (en)
Inventor
Frederick H Hausheer
Thomas J Dodd
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1033981T3 publication Critical patent/DK1033981T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98953570T 1997-10-17 1998-10-16 Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet DK1033981T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,678 US5919816A (en) 1994-11-14 1997-10-17 Formulations and methods of reducing toxicity of antineoplastic agents
PCT/US1998/021814 WO1999020264A1 (en) 1997-10-17 1998-10-16 Formulations and methods for reducing toxicity of antineoplastic agents

Publications (1)

Publication Number Publication Date
DK1033981T3 true DK1033981T3 (da) 2004-07-12

Family

ID=25495777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98953570T DK1033981T3 (da) 1997-10-17 1998-10-16 Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet

Country Status (12)

Country Link
US (11) US5919816A (OSRAM)
EP (1) EP1033981B1 (OSRAM)
JP (3) JP2001520189A (OSRAM)
CN (1) CN1276720A (OSRAM)
AT (1) ATE262329T1 (OSRAM)
AU (1) AU750521B2 (OSRAM)
CA (1) CA2304704C (OSRAM)
DE (1) DE69822659T2 (OSRAM)
DK (1) DK1033981T3 (OSRAM)
ES (1) ES2213922T3 (OSRAM)
PT (1) PT1033981E (OSRAM)
WO (1) WO1999020264A1 (OSRAM)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6075053A (en) * 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
US20030036513A1 (en) * 1999-02-16 2003-02-20 Yurkow Edward J. Method for treating cancer
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
AU777528B2 (en) * 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
JP2003514033A (ja) * 1999-11-15 2003-04-15 パーカー ヒューズ インスティテュート 癌治療用のホルボキサゾール誘導体
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
GB0011927D0 (en) * 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
CA2427467C (en) 2000-11-09 2010-01-12 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
JP2004523518A (ja) * 2001-01-19 2004-08-05 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド より効能が大きく副作用の少ない癌治療方法
US20030149096A1 (en) * 2001-02-05 2003-08-07 Pezzuto John M. Cancer chemopreventative compounds and compositions and methods of treating cancers
RU2284184C2 (ru) * 2001-03-06 2006-09-27 Бристол-Маерс Сквибб Компани Способ лечения рака
JP2004519493A (ja) * 2001-03-19 2004-07-02 ノバルティス アクチエンゲゼルシャフト 抗下痢剤およびエポチロンまたはエポチロン誘導体を含む組合せ剤
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
EP2100617A1 (en) 2002-03-15 2009-09-16 Schering Corporation Methods of modulating CD200 receptors
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
MXPA04011322A (es) * 2002-05-17 2005-02-17 Leo Pharma As Profarmacos de cianoguanidina.
WO2003097602A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine produgs
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
CA2485794C (en) * 2002-05-31 2012-10-16 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
US20040127435A1 (en) * 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
NZ538584A (en) * 2002-09-05 2007-05-31 Bharat Serums & Vaccines Ltd Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2004054569A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
EA200501252A1 (ru) * 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
US7807350B2 (en) * 2003-05-30 2010-10-05 The University Of Chicago Methods for predicting irinotecan toxicity
US20040266808A1 (en) * 2003-06-27 2004-12-30 Kamen Barton A. Treatment of antifolate neurotoxicity
PL2263694T3 (pl) * 2003-09-25 2013-11-29 Astellas Pharma Inc Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
WO2005077008A2 (en) * 2004-02-09 2005-08-25 Pharmagenesis, Inc. Methods for isolation of triptolide compounds from tripterygium wilfordii
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
AU2005218610B2 (en) * 2004-03-02 2011-08-18 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7200207B2 (en) * 2004-03-13 2007-04-03 Intrado Inc. Communication network for providing emergency services
EP1804816B1 (en) * 2004-03-26 2011-12-21 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine(tm)
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
ATE552233T1 (de) 2004-08-20 2012-04-15 Univ Virginia Patent Found T-typ-calciumkanalinhibitoren
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
CA2594508C (en) * 2004-12-22 2013-10-01 Leo Pharma A/S Cyanoguanidine compounds
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
AU2006326442B2 (en) * 2005-12-13 2012-03-01 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AU2008214199A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
EP2131849B1 (en) * 2007-03-02 2011-10-26 The University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
US8211912B2 (en) * 2007-09-26 2012-07-03 Gemin X Pharmaceuticals Canada Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
WO2009067489A1 (en) * 2007-11-20 2009-05-28 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
JP2011511072A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
WO2009114325A2 (en) * 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
WO2009111648A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
CN102014891B (zh) * 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
JP5694782B2 (ja) * 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 肺癌、腺癌及び他の病状のための治療方法及び組成物
WO2010132771A1 (en) 2009-05-15 2010-11-18 Lankenau Institute For Medical Research Methods and kits for measuring toxicity and oxidative stress in live cells
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
WO2012021963A1 (en) 2010-07-09 2012-02-23 Metasignal Therapeutics Inc. Novel sulfonamide compounds for inhibition of metastatic tumor growth
US9271952B2 (en) * 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
CN102871991B (zh) * 2012-10-24 2014-06-18 中国医学科学院放射医学研究所 二甲双胍在对放化疗损伤起保护作用的药物中的应用
CA2919837A1 (en) * 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
US9470029B2 (en) 2014-05-30 2016-10-18 Pella Corporation Casement pivot arm roller hinge
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
CN108430466A (zh) 2015-10-02 2018-08-21 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents

Also Published As

Publication number Publication date
EP1033981B1 (en) 2004-03-24
JP2006070041A (ja) 2006-03-16
DE69822659D1 (de) 2004-04-29
DE69822659T2 (de) 2004-08-12
US6040312A (en) 2000-03-21
ATE262329T1 (de) 2004-04-15
US6066645A (en) 2000-05-23
CA2304704A1 (en) 1999-04-29
US6057361A (en) 2000-05-02
JP2010043117A (ja) 2010-02-25
US5919816A (en) 1999-07-06
EP1033981A1 (en) 2000-09-13
US6040294A (en) 2000-03-21
JP2001520189A (ja) 2001-10-30
PT1033981E (pt) 2004-08-31
US6040304A (en) 2000-03-21
US6046234A (en) 2000-04-04
US6066668A (en) 2000-05-23
WO1999020264A1 (en) 1999-04-29
US6046159A (en) 2000-04-04
CN1276720A (zh) 2000-12-13
CA2304704C (en) 2009-01-13
US6048849A (en) 2000-04-11
US6043249A (en) 2000-03-28
EP1033981A4 (en) 2001-10-04
AU1090899A (en) 1999-05-10
AU750521B2 (en) 2002-07-18
ES2213922T3 (es) 2004-09-01

Similar Documents

Publication Publication Date Title
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
MY118151A (en) Pharmaceutical formulations containing voriconazole.
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
EP0722324A4 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
ATE195721T1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
DE69525291D1 (de) Bisphosphonat und anti-Resorption Agentien, enthaltende Zusammensetzungen zur Hemmung der Knochenschwund
DK0998287T3 (da) Anvendelse af levobupivacain
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
DE69322251D1 (de) Medizinische zusammensetzung
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
GEP20043377B (en) Pharmaceutical Complex
DE69626544T2 (de) Arzneistoffe
GB9211277D0 (en) Pharmaceutical compositions
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol